Physician

Linda K Hendricks, M.D.

According to 2025 Medicare claims, Linda Hendricks, M.D. (NPI: 1881639821) practices hematology/oncology in the Warner Robins, GA market, with the plurality of this provider's patient population coming from Houston, GA. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 31088-9998. Hendricks is affiliated with the TC2, LLC (ACO ID: A3365), participating under the MSSP model.

Hendricks' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,623 traditional Medicare patients, billed 290,662 HCPCS/CPT codes, and received $5,390,542 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,543 prescription claims across 602 beneficiaries totaling $5,724,364 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 49 claims. Open Payments data shows 43 records totaling $872. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,644,322 to $5,390,542. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,044,616 to $5,724,364. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,301 and ending at $8,020.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,092	119,423	$1,644,322
2016	1,042	103,817	$1,700,665
2017	1,245	157,392	$2,285,282
2018	1,400	178,533	$2,880,525
2019	1,747	330,242	$5,172,289
2020	1,569	277,590	$4,105,559
2021	1,707	331,453	$5,356,058
2022	1,605	245,242	$4,259,076
2023	1,693	300,872	$4,671,743
2024	1,623	290,662	$5,390,542

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	290	2,150	$1,044,616
2016	289	1,947	$948,015
2017	328	1,761	$1,344,755
2018	407	2,023	$1,407,017
2019	457	1,990	$1,092,915
2020	419	2,116	$2,080,194
2021	475	2,052	$2,727,588
2022	497	2,156	$3,776,168
2023	548	2,433	$4,708,462
2024	602	2,543	$5,724,364

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	47	155	$26,851
2016	11	95	$4,737
2017	13	62	$1,551
2018	34	189	$15,309
2019	53	259	$10,172
2020	58	227	$10,446
2021	11	120	$5,436
2022	24	159	$5,953
2023	25	120	$9,939
2024	N/R	49	$2,616

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	955	1,633	$93
82728	Ferritin (blood protein) level	541	752	$13
80053	Blood test, comprehensive group of blood chemicals	1,001	2,155	$10
83550	Iron binding capacity	459	604	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,187	2,787	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	83	2,490	$1,235,202
Revlimid	Lenalidomide	45	1,239	$770,614
Lenalidomide	Lenalidomide	45	1,253	$721,906
Ibrance	Palbociclib	36	1,031	$570,342
Calquence	Acalabrutinib Maleate	17	510	$251,452

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	12	$1,284
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	12	$603
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest	Y	N/R	12	$566
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	43	$872	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Linda K. Hendricks, M.D.?

Tedicare shows public-source Medicare data for Linda K. Hendricks, M.D. (NPI 1881639821), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Linda K. Hendricks, M.D. have ACO affiliation data?

Linda K. Hendricks, M.D. is shown with ACO affiliation data for TC2, LLC (MSSP, ACO ID A3365).

What billing organization is linked to Linda K. Hendricks, M.D.?

Linda K. Hendricks, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Linda K. Hendricks, M.D. have Open Payments data?

Linda K. Hendricks, M.D. has 43 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.